Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results ...
Oct 20, 2013